-
9m 38sPart 3 | Session 1 ACC 22: Findings from the VALOR-HCM Trial
-
7m 19s
-
3m 19sPart 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial
-
3m 6s
-
3m 54sPart 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial
-
4m 22sPart 3 | Session 6 ACC 22: Results from the POISE-3 Trial
-
6m 30sPart 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia
-
6m 3s
-
3m 31sPart 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)
-
4m 48sPart 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial
-
2m 55sPart 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials
-
7m 44sPart 3 | Session 12 ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR
-
5m 41sPart 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study
-
2m 25sPart 3 | Session 14 ACC 22: Results from the GIPS-IV Trial
-
9m 27s
-
5m 35s
-
10m 24s
-
3m 50sPart 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study
-
4mPart 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation
-
12m 6sPart 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani
-
6m 15s
-
7m 9sPart 4 | Session 3 4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos
-
23m 9sPart 1 | Session 1 ACC 22 Late-breaking Science Preview
-
28m 6sPart 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up
-
16m 42sPart 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial
-
16m 57sPart 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial
-
15m 38sPart 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Late-breaker Discussion Series
Part 3
Expert Interviews
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an internationally known cardiologist, research methodologist, and senior scientist. She serves as an Associate Professor of Medicine at McMaster University, a Senior Scientist at the Population Health Research Institute, and Director of Implementation Science at the Baim Institute for Clinical Research in Boston.
Academic history
Dr Van Spall completed her BSc and MD at the University of Toronto, followed by residency and fellowship training in internal medicine and…
Javed Butler
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.
He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.
Faiez Zannad
Professor Emeritus; Founder and Chairman of CVCT Société Civile
Prof Faiez Zannad was born in Monastir, Tunisia in 1951 and later moved to pursue his medical education and research in Europe. He trained in cardiology and pharmacology across institutions in France and the United Kingdom, including Nancy, Lyon, and Oxford. Over the course of his career, he has lived and worked primarily in Nancy, France, where he has held clinical, academic, and research leadership roles in cardiovascular medicine and therapeutics.
Academic History
Prof Zannad earned his MD in cardiology from the Faculté de Médecine de Nancy and further trained as a research fellow in clinical pharmacology at the Medical Research Council in Oxford. He later received a PhD in cardiovascular clinical pharmacology from the University of Lyon. During his academic training, he focused on cardiovascular pharmacology, physiology, and therapeutic innovation, laying the foundation for his lifelong work in heart failure and hypertension research.
Following…